Time to Reassess Tocilizumab’s Role in COVID-19 Pneumonia via part of
Time to Reassess Tocilizumab’s Role in COVID-19 Pneumonia | Very Nice Editorial on studies evaluating tocilizumab⁩ ⁦
"Time to Reassess Tocilizumab’s Role in #COVID19 Pneumonia" In short from 2 randomized clinical trial no proven efficacy for Tocilizumab (anti-IL6) -> "not support the routine use of tocilizumab for COVID-19 in most settings" Again no silver bullets
Unlike previous observational studies, RCTs aren’t showing convincing benefit with tocilizumab, but 5 other RCTs of tocilizumab in #COVID19 are underway including the huge #RECOVERYtrial, so watch this space.
Where we are with #tocilizumab for #COVID19 . Neat summary in . The fact remains that we need good RCT data. The observational studies so far are small, flawed and show conflicting results. Given the $$$ of drug must have clearer evidence of benefit.
Two new RCTs just out show no/limited (nothing on mortality) benefits of #Tocilizumab in #SARSCoV2. Large observational study in same issue show reduced mortality. Get popcorn.
Nice summary of where we are with Tocilizumab. Jonathan Parr say: "I plan to wait out the torrent of positive observational studies and reconsider tocilizumab’s use in COVID-19 if, and only if, more compelling data from randomized trials emerges.
Time to Reassess Tocilizumab’s Role in COVID-19 Pneumonia via part of
Time to Reassess Tocilizumab’s Role in COVID-19 Pneumonia